Biomarker Analysis Europe
Hear from and meet with the leading figures in biomarker analysis to explore how companies are innovating in biomarker analysis to accelerate timelines and reduce risk in drug development, with in-depth consideration of the latest multiplexed and cytometry tools impacting biomarker research & validation
Our Postdoctoral Scientist, Dr Lucy Frost will be discussing ‘Is the bleomycin model of pulmonary fibrosis a bad model, or just used badly?’ on 1 November, 5pm.
